CA2212440A1 - Pharmaceutical preparations for tnf inhibition - Google Patents

Pharmaceutical preparations for tnf inhibition

Info

Publication number
CA2212440A1
CA2212440A1 CA002212440A CA2212440A CA2212440A1 CA 2212440 A1 CA2212440 A1 CA 2212440A1 CA 002212440 A CA002212440 A CA 002212440A CA 2212440 A CA2212440 A CA 2212440A CA 2212440 A1 CA2212440 A1 CA 2212440A1
Authority
CA
Canada
Prior art keywords
pharmaceutical preparations
tnf inhibition
tnf
inhibition
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002212440A
Other languages
French (fr)
Other versions
CA2212440C (en
Inventor
Hermann Graf
Helmut Wachtel
Herbert Schneider
Daryl Faulds
Daniel Perez
Harald Dinter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering Aktiengesellschaft
Hermann Graf
Helmut Wachtel
Herbert Schneider
Daryl Faulds
Daniel Perez
Harald Dinter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft, Hermann Graf, Helmut Wachtel, Herbert Schneider, Daryl Faulds, Daniel Perez, Harald Dinter filed Critical Schering Aktiengesellschaft
Priority claimed from PCT/DE1996/000257 external-priority patent/WO1996024350A1/en
Publication of CA2212440A1 publication Critical patent/CA2212440A1/en
Application granted granted Critical
Publication of CA2212440C publication Critical patent/CA2212440C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione

Abstract

The use of the compounds of formula I
(see formula I) for treating TNF-mediated diseases is described.
CA002212440A 1995-02-10 1996-02-09 Pharmaceutical preparations for tnf inhibition Expired - Fee Related CA2212440C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19505516.0 1995-02-10
DE19505516 1995-02-10
PCT/DE1996/000257 WO1996024350A1 (en) 1995-02-10 1996-02-09 Pharmaceutical preparations for tumour necrosis factor (tnf) inhibition

Publications (2)

Publication Number Publication Date
CA2212440A1 true CA2212440A1 (en) 1996-08-15
CA2212440C CA2212440C (en) 2006-10-03

Family

ID=37101756

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002212440A Expired - Fee Related CA2212440C (en) 1995-02-10 1996-02-09 Pharmaceutical preparations for tnf inhibition

Country Status (1)

Country Link
CA (1) CA2212440C (en)

Also Published As

Publication number Publication date
CA2212440C (en) 2006-10-03

Similar Documents

Publication Publication Date Title
AU6124996A (en) Certain arylsulfonamido-substituted hydroxamic acids for the treatment of certain tumors
AU1402895A (en) Use of pla2 inhibitors as treatment for alzheimer's disease
AU1088695A (en) 1,5-diphenyl pyrazole compounds for treatment of inflammation
AU7867994A (en) Hemofiltration of mediator-related diseases
AU5086093A (en) Process for the preparation of etbe
AU4048295A (en) Peptide medicaments for the treatment of disease
AU2388895A (en) Substituted cyclopentadienyl compounds for the treatment of inflammation
AU3634095A (en) Inhibition of hemoflagellates by camptothecin compounds
AU4960297A (en) Bicyclic aryl carboxamides and their therapeutic use
AU5033293A (en) Process for the preparation of aromatic bromomethyl compounds
CA2204747A1 (en) New azo derivatives of 5-aminosalicylic acid
AU1450392A (en) Small peptidic compounds useful for the treatment of glaucoma
IT1271567B (en) PROCEDURE FOR THE FURTHER TREATMENT OF SALCICCE
AU4220193A (en) Deazaaminopterins for treatment of inflammation
AU1142192A (en) Process for the preparation of 13c-labelled compounds
AU3027692A (en) Compositions for the treatment of mammalian diseases
NZ504051A (en) Crystalline polymorphs of 1,3-di-cyclopropylmethyl-8-amino xanthine (cypamfylline), and the use of these compounds for treating PDE4 or TNF mediated diseases
AU5526196A (en) Compositions for the treatment of dandruff
AU3673293A (en) Process for the preparation of cinnamic acid derivatives
AU6301094A (en) The use of compositions for combating tumour diseases
CA2212440A1 (en) Pharmaceutical preparations for tnf inhibition
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
AU8185491A (en) Treatment of disease
AU5252793A (en) Therapeutic for gram-positive diseases of aquatic species
AU4019395A (en) Use of amino-isoxazolidone compounds for improvement of implicit memory

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed